GKOS · Glaukos Corp
Price
Snapshot
50 fields · last close| Market Cap | $9.77B |
| P/E | — |
| Float | 56.86M |
| Beta | 0.73 |
| Volatility | 18.2% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 73.2 |
| Price | 164.84 |
| Change | +0.00% |
| Prev Close | 164.84 |
| Open | 168.26 |
| Day Low | 165.36 |
| Day High | 170.20 |
| Avg Vol | 1 |
| Avg $ Vol | $183.0M |
| 52W High | 191.62 |
| 52W Low | 73.16 |
| 52W Pos | 77.4% |
| From High | −13.98% |
| From Low | +125.31% |
| Max DD 1Y | −28.39% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.50% |
| SMA 50 | −4.44% |
| SMA 200 | +20.05% |
| RSI (14) | 49.6 |
| Vol 30D | 45.0% |
| Vol 90D | 38.5% |
| 1Y Range | 73–192 |
| Daily bars | 535 |
| Perf Week | +2.67% |
| Perf Month | +1.30% |
| Perf Quarter | +5.59% |
| Perf Half Y | +36.16% |
| Perf Year | +94.09% |
| Perf YTD | +48.88% |
| Prev Day | +0.00% |
| Clavix | B |
| Debt / Eq | 0.01 |
| Curr Ratio | 4.69 |
| Int Cover | -74.1× |
| FCF Margin | −4.4% |
| Rev Growth | +32.3% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 34 / 49 |
Clavix risk grade
regraded every trading dayGKOS grades B, 73.2 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (57, mixed). 0 of the 4 weighted dimensions sit above the Health Care median. Ranks 34 of 49 in Health Care by Clavix score.
How rough the ride is
| GKOS | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.73 | 0.84 |
| Volatilityannualized | 18.2% | 21.1% |
| Max drawdown, past yearworst peak-to-trough fall | −28.4% | — |
| Typical daily movemedian absolute daily change | 1.53% | — |
| Days beyond ±3%of the last 252 sessions | 54 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| GKOS | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.73 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| GKOS | |
|---|---|
| 1 week | +2.7% |
| 1 month | +1.3% |
| Year to date | +48.9% |
| 1 year | +94.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| GKOS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 29 Jul |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 2 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| GKOS | |
|---|---|
| Revenue growthyear over year | +32.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openGlaukos reported Q2 net sales up 50% year-over-year to $185.6M, driven by its iDose TR eye implant and the Epioxa launch, with profit margins reaching 85% on an adjusted basis and a breakeven bottom line. Management raised its 2026 sales outlook to $680-700M, including $275-280M from iDose TR and 20%+ growth in corneal health.
Glaukos has expanded its eye-drug pipeline by licensing a treatment called RO-104 from RevOpsis and gaining exclusive rights to RevOpsis's RevMod drug-delivery platform. Shares fell 6.3%. No specific catalyst was identified.
Glaukos signed a licensing deal with RevOpsis to bring in the eye drug RO-104 and gain exclusive rights to the RevMod drug platform, adding to its pipeline of treatments for diseases of the retina (the back of the eye). Shares fell 6.3%. No specific catalyst was identified.
Glaukos announced positive topline results from a Phase 4 randomized controlled trial (GLK-101-04) testing its iDose TR implant given alongside cataract surgery against cataract surgery alone in patients with open-angle glaucoma.
Glaukos released positive three-year follow-up data from a Phase 3 extension study of Epioxa, its eye-drop treatment for keratoconus (a sight-threatening, often-undiagnosed corneal condition), and separately signed an exclusive licensing deal to bring in new retinal disease therapies.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| HSIC | Henry Schein Inc | A- | $9.69B | 24.08 | 0.87 | Compare |
| PODD | Insulet Corp | B- | $9.62B | 25.40 | 1.08 | Compare |
| GMED | Globus Medical Inc | B | $10.59B | 19.14 | 0.97 | Compare |
| ALGN | Align Technology Inc | B | $10.61B | 25.36 | 1.74 | Compare |
| COO | Cooper Companies Inc | B- | $10.91B | 18.60 | 0.83 | Compare |
| UHS | Universal Health Services Inc | A- | $11.04B | 7.27 | 1.12 | Compare |
| MOH | Molina Healthcare Inc | B | $11.09B | 23.41 | 0.74 | Compare |
| HNGE | Hinge Health Inc | C+ | $8.47B | 77.65 | 1.50 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.